Cancer immunogenicity, danger signals, and DAMPs: What, when, and how?
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Cancer immunosurvelliance usually leads to formation of cancer cells that have been “immunoedited” to resist anti‐tumor immunity. One of the consequences of immunoediting that is, reduced immunogenicity, is an important roadblock in revival of stable and long‐lasting anti‐tumor immune responses. Research done during the last decade has shown that emission by the dying cancer cells of immunomodulatory factors or damage‐associated molecular patterns (DAMPs), which can act as danger signals, is a critical event in accentuating the immunogenicity of cancer cells, in response to a subset of anticancer treatments. Recent evidence has defined that an apoptotic cell death subroutine and its underlying biochemistry, which has been termed as “immunogenic cell death (ICD)” or “immunogenic apoptosis,” is required for the efficient emission of DAMPs and inciting anti‐tumor immunity. Here, we review the basic concepts of ICD, like cancer immunogenicity, danger signals, and DAMPs. Moreover, we discuss the emerging molecular links between endoplasmic reticulum (ER) stress, induction of a viral response‐like gene expression, danger signals, and anti‐tumor immunity. We envisage that along with ER stress‐based trafficking of DAMPs (which is a “short‐range communicator” of danger), the accompanying induction of a viral response‐like gene expression and the secretion of anti‐tumorigenic cytokines may become a crucial signature of ICD induction by anticancer therapy. © 2013 BioFactors, 39(4):355–367, 2013
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981 · cited 1×
“This is because in most cases, Th1 cells and IFN-c production rather than Th2 cells and IL-10 production (in tumors) have been found to strongly associate with positive clinical outcomes in cancer patients [57].”
BackgroundThe Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205
Circulating mitochondrial DAMPs cause inflammatory responses to injury
Zhang, Q., Raoof, M., Chen, Y., Sumi, Y., Sursal, T., Junger, W., Brohi, K., Itagaki, K., & Hauser, C. J. (2010) · Nature · doi:10.1038/nature08780 · Cited by 3,812
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303 · cited 9×
“It is well established now that in order to activate potent anti-tumor immunity (as happens in the case of ICD [5,25,27,33]), DAMPs-based immunogenicity is required to establish a dying cancer cell-DC interface (preferably consisting of TLR stimulation and devoid of immunosuppressive factors like IL-10) that ultimatel…”
BackgroundInfluentialImmunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Self-citationCalreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216 · cited 7×
“Pre-apoptotic DAMP trafficking: The most described preapoptotic DAMP trafficking event is the surface exposure of CRT (by anthracyclines [32], oxaliplatin [92], UVC [93], ionizing-irradiation [93–95], 7A7 [96], cyclophosphamide [5,28], Hyp-PDT [24,33,51], CVB3 [97]).”
BackgroundInfluentialFadok, V. A., Bratton, D. L., Konowal, A., Freed, P. W., Westcott, J. Y., & Henson, P. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1112 · Cited by 3,166 · cited 5×
“Ability to induce immunotolerance or active immunosuppression: through immunosuppressive cytokines like IL-10 [8,9] or transforming growth factor-beta (TGF-b) [10,11]; or expression of immune cell checkpoint ligands that inhibit anti-tumor immunity [12]; 3.”
BackgroundInfluentialApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 4×
“Various immune cells like the natural killer (NK) cells, dendritic cells (DCs), and T cells actively participate in recognition and elimination of such newly formed immunogenic neoplastic cells during this phase [2,3].”
BackgroundInfluentialDAMPs, PAMPs and alarmins: all we need to know about danger
Bianchi, M. E. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0306164 · Cited by 2,794
Cited by
Consensus guidelines for the detection of immunogenic cell death
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832
Self-citationPhotodynamic therapy in cancer treatment - an update review
Dos Santos, A. F., De Almeida, D. R. Q., Terra, L. F., Baptista, M. S., & Labriola, L. (2019) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2018.83 · Cited by 446
Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses
Garg, A. D., & Agostinis, P. (2017) · Immunological Reviews · doi:10.1111/imr.12574 · Cited by 440
Self-citationMolecular and Translational Classifications of DAMPs in Immunogenic Cell Death
Garg, A. D., Galluzzi, L., Apetoh, L., Baert, T., Birge, R. B., Bravo-San Pedro, J. M., Breckpot, K., Brough, D., Chaurio, R., Cirone, M., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00588 · Cited by 410
Self-citationDudek, A. M., Martin, S., Garg, A. D., & Agostinis, P. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00438 · Cited by 399
Self-citation
Metadata
- Authors
- Garg, A. D., Dudek, A. M., & Agostinis, P.
- Venue
- BioFactors
- Publisher
- Wiley
- Published
- 2013-07
- Volume
- 39
- Issue
- 4
- Pages
- 355-367
- ISSN
- 0951-6433 (ISSN-L)
- 1872-8081
- OpenAlex
- W1530610894
- Cited by
- 108
- References
- 33
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cancer immunogenicity, danger signals, and DAMPs: What, when, and how? https://app.cochat.ai/papers/10.1002/biof.1125
- The paper
- Garg, A. D., Dudek, A. M., & Agostinis, P. (2013). Cancer immunogenicity, danger signals, and DAMPs: What, when, and how? BioFactors. https://doi.org/10.1002/biof.1125
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.